337 related articles for article (PubMed ID: 22198344)
1. Pathophysiology of the cardiac late Na current and its potential as a drug target.
Moreno JD; Clancy CE
J Mol Cell Cardiol; 2012 Mar; 52(3):608-19. PubMed ID: 22198344
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
Undrovinas AI; Belardinelli L; Undrovinas NA; Sabbah HN
J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1(Suppl 1):S169-S177. PubMed ID: 16686675
[TBL] [Abstract][Full Text] [Related]
3. A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current.
Yang PC; Song Y; Giles WR; Horvath B; Chen-Izu Y; Belardinelli L; Rajamani S; Clancy CE
J Physiol; 2015 Mar; 593(6):1429-42. PubMed ID: 25545172
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
5. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability.
Maltsev VA; Silverman N; Sabbah HN; Undrovinas AI
Eur J Heart Fail; 2007 Mar; 9(3):219-27. PubMed ID: 17067855
[TBL] [Abstract][Full Text] [Related]
6. The role of late I Na in development of cardiac arrhythmias.
Antzelevitch C; Nesterenko V; Shryock JC; Rajamani S; Song Y; Belardinelli L
Handb Exp Pharmacol; 2014; 221():137-68. PubMed ID: 24737235
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.
Moreno JD; Yang PC; Bankston JR; Grandi E; Bers DM; Kass RS; Clancy CE
Circ Res; 2013 Sep; 113(7):e50-e61. PubMed ID: 23897695
[TBL] [Abstract][Full Text] [Related]
8. Role of late sodium channel current block in the management of atrial fibrillation.
Burashnikov A; Antzelevitch C
Cardiovasc Drugs Ther; 2013 Feb; 27(1):79-89. PubMed ID: 23108433
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of physiological late Na
El-Bizri N; Li CH; Liu GX; Rajamani S; Belardinelli L
Am J Physiol Heart Circ Physiol; 2018 Feb; 314(2):H236-H245. PubMed ID: 28971840
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology and pharmacology of the cardiac "late sodium current.".
Zaza A; Belardinelli L; Shryock JC
Pharmacol Ther; 2008 Sep; 119(3):326-39. PubMed ID: 18662720
[TBL] [Abstract][Full Text] [Related]
11. Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice.
Yao L; Fan P; Jiang Z; Viatchenko-Karpinski S; Wu Y; Kornyeyev D; Hirakawa R; Budas GR; Rajamani S; Shryock JC; Belardinelli L
Am J Physiol Cell Physiol; 2011 Sep; 301(3):C577-86. PubMed ID: 21677263
[TBL] [Abstract][Full Text] [Related]
12. Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes.
Fredj S; Lindegger N; Sampson KJ; Carmeliet P; Kass RS
Circ Res; 2006 Nov; 99(11):1225-32. PubMed ID: 17082480
[TBL] [Abstract][Full Text] [Related]
13. Late sodium current associated cardiac electrophysiological and mechanical dysfunction.
Yu S; Li G; Huang CL; Lei M; Wu L
Pflugers Arch; 2018 Mar; 470(3):461-469. PubMed ID: 29127493
[TBL] [Abstract][Full Text] [Related]
14. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
[TBL] [Abstract][Full Text] [Related]
15. Late sodium current is a novel target for amiodarone: studies in failing human myocardium.
Maltsev VA; Sabbah HN; Undrovinas AI
J Mol Cell Cardiol; 2001 May; 33(5):923-32. PubMed ID: 11343415
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of late Na+ current, a novel target to improve diastolic function and electrical abnormalities in Dahl salt-sensitive rats.
Chi L; Belardinelli L; Zeng A; Hirakawa R; Rajamani S; Ling H; Dhalla AK
Am J Physiol Heart Circ Physiol; 2016 May; 310(10):H1313-20. PubMed ID: 26993228
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Makielski JC; Valdivia CR
Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
[TBL] [Abstract][Full Text] [Related]
18. About half of the late sodium current in cardiac myocytes from dog ventricle is due to non-cardiac-type Na(+) channels.
Biet M; Barajas-MartÃnez H; Ton AT; Delabre JF; Morin N; Dumaine R
J Mol Cell Cardiol; 2012 Nov; 53(5):593-8. PubMed ID: 22759452
[TBL] [Abstract][Full Text] [Related]
19. Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na
El-Bizri N; Xie C; Liu L; Limberis J; Krause M; Hirakawa R; Nguyen S; Tabuena DR; Belardinelli L; Kahlig KM
Heart Rhythm; 2018 Feb; 15(2):277-286. PubMed ID: 29017927
[TBL] [Abstract][Full Text] [Related]
20. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.
Antoons G; Oros A; Beekman JD; Engelen MA; Houtman MJ; Belardinelli L; Stengl M; Vos MA
J Am Coll Cardiol; 2010 Feb; 55(8):801-9. PubMed ID: 20170820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
